Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SFOSF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
-3%
0.07
vs 0.07
Q1.23
+97%
0.05
vs 0.03
Q2.23
-33%
0.04
vs 0.06
Q3.23
-45%
0.03
vs 0.05
Q4.23
-92%
0.01
vs 0.07
Q1.24
-41%
0.03
vs 0.05
Q2.24
-22%
0.03
vs 0.04
Q3.24
+62%
0.04
vs 0.03
Q4.24
+615%
0.04
vs 0.01
Q1.25
+25%
0.04
vs 0.03
Sales Growth
YoY
Current
Estimates
Q1.23
+5%
10.9B vs 10.4B
Q2.23
-4%
10.5B vs 11B
Q3.23
-9%
9.3B vs 10.3B
Q4.23
-14%
10.6B vs 12.3B
Q1.24
-7%
10.1B vs 10.9B
Q2.24
-3%
10.2B vs 10.5B
Q3.24
+12%
10.4B vs 9.3B
Q4.24
-4%
10.2B vs 10.6B
Q1.25
-6%
9.4B vs 10.1B
Q2.25
+587%
70.3B vs 10.2B
Return on Equity
QoQ
Q2.23
+2%
0.02
vs 0.02
Q3.23
+1%
0.01
vs 0.02
Q4.23
+0%
0
vs 0.01
Q1.24
+1%
0.01
vs 0
Q2.24
+1%
0.01
vs 0.01
Q3.24
+2%
0.02
vs 0.01
Q4.24
+2%
0.02
vs 0.02
Q1.25
+2%
0.02
vs 0.02
Institutionnal Ownership
seekingalpha.com
9 hours ago
seekingalpha.com
11 hours ago
seekingalpha.com
14 hours ago
reuters.com
15 hours ago
seekingalpha.com
17 hours ago
forbes.com
22 hours ago
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
OTC
Relative Strenght
Volume Buzz
400%
Earning Acce
No
Dist 52w H.
13%Forecast
389%2026-Revenue
368%2026-EPS
391%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
SFOSF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics